351 results on '"Vega, Francisco"'
Search Results
2. Lower Eocene gastropods from the El Bosque Formation, central Chiapas, Mexico
- Author
-
Del Carmen Perrilliat, María, Avendaño, Javier, Vega, Francisco J, Solé, Jesús, and BioStor
- Published
- 2006
3. A new fossil frog crab (Brachyura, Raninoidea) from the late Campanian of Hornby Island (British Columbia, Canada)
- Author
-
Nyborg, Torrey, Garassino, Alessandro, Vega, Francisco J., and Ross, Richard L.M.
- Abstract
We report a new fossil crab from the late Campanian of the Northumberland Formation, Hornby Island (British Columbia, Canada). The studied specimen has been assigned to Bournelyreidus with B. grahamae n. sp. It represents the first report of the genus from Canada, extending its palaeogeographic distribution in the eastern Pacific. Finally, it represents the seventh species of the genus, confirming the restricted stratigraphic age of the genus to the Late Cretaceous.
- Published
- 2024
- Full Text
- View/download PDF
4. Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6copy number variation, and phenoconversion in 15,000 patients
- Author
-
Patel, Jai N., Morris, Sarah A., Torres, Raul, Rhead, Brooke, Vlangos, Chris, Mueller, Daniel J., Brown, Lisa C., Lefkofsky, Hailey, Ali, Muneer, De La Vega, Francisco M., Barnes, Kathleen C., Zoghbi, Anthony, Stanton, Joseph D., and Badgeley, Marcus A.
- Abstract
Pharmacogenomic testing has emerged as an aid in clinical decision making for psychiatric providers, but more data is needed regarding its utility in clinical practice and potential impact on patient care. In this cross-sectional study, we determined the real-world prevalence of pharmacogenomic actionability in patients receiving psychiatric care. Potential actionability was based on the prevalence of CYP2C19 and CYP2D6 phenotypes, including CYP2D6 allele-specific copy number variations (CNVs). Combined actionability additionally incorporated CYP2D6 phenoconversion and the novel CYP2C-TG haplotype in patients with available medication data. Across 15,000 patients receiving clinical pharmacogenomic testing, 65% had potentially actionable CYP2D6 and CYP2C19 phenotypes, and phenotype assignment was impacted by CYP2D6allele-specific CNVs in 2% of all patients. Of 4114 patients with medication data, 42% had CYP2D6 phenoconversion from drug interactions and 20% carried a novel CYP2Chaplotype potentially altering actionability. A total of 87% had some form of potential actionability from genetic findings and/or phenoconversion. Genetic variation detected via next-generation sequencing led to phenotype reassignment in 22% of individuals overall (2% in CYP2D6 and 20% in CYP2C19). Ultimately, pharmacogenomic testing using next-generation sequencing identified potential actionability in most patients receiving psychiatric care. Early pharmacogenomic testing may provide actionable insights to aid clinicians in drug prescribing to optimize psychiatric care.
- Published
- 2024
- Full Text
- View/download PDF
5. Hemodialysis Catheter Breakage in an Infant
- Author
-
Nieto-Vega, Francisco A, García-Rojas, Ángela, Moreno-González, Inmaculada, Martínez-Rivera, Verónica, Rodríguez-Mesa, José M, and Rosa-Camacho, Vanessa
- Abstract
A 3-month-old male infant was admitted to our unit due to acute decompensation of chronic kidney disease of unknown etiology. Further investigation led to the diagnosis of primary hyperoxaluria type 1. As the patient did not recover, hemodialysis was initiated with a non-tunneled femoral catheter. A tunneled Hickman catheter was placed in the internal jugular vein. The patient experienced moderate intradialytic exit-site bleeding and catheter malfunction, which initially responded to pressure and postural changes. During the third session, the patient suffered cardiopulmonary arrest. After stabilization, a chest hematoma was identified. Fluoroscopy revealed a catheter breakage. Despite initial stabilization, the patient developed septic shock due to Pseudomonas aeruginosaand died several days later. Hemodialysis is sometimes necessary in children under 24 months with chronic kidney disease. Vascular access is a major challenge in these patients due to lack of appropriate catheter sizes and high complication rates. Hemodialysis catheter fracture is an uncommon complication, and diagnosis can be difficult when the breakage involves the subcutaneous segment. Persistent intradialytic bleeding and mechanical malfunction should raise suspicion of this complication and should elicit catheter revision under fluoroscopy. Without prompt diagnosis, catheter breakage may have fatal consequences, as in our case.
- Published
- 2023
- Full Text
- View/download PDF
6. The status of the human gene catalogue
- Author
-
Amaral, Paulo, Carbonell-Sala, Silvia, De La Vega, Francisco M., Faial, Tiago, Frankish, Adam, Gingeras, Thomas, Guigo, Roderic, Harrow, Jennifer L., Hatzigeorgiou, Artemis G., Johnson, Rory, Murphy, Terence D., Pertea, Mihaela, Pruitt, Kim D., Pujar, Shashikant, Takahashi, Hazuki, Ulitsky, Igor, Varabyou, Ales, Wells, Christine A., Yandell, Mark, Carninci, Piero, and Salzberg, Steven L.
- Abstract
Scientists have been trying to identify every gene in the human genome since the initial draft was published in 2001. In the years since, much progress has been made in identifying protein-coding genes, currently estimated to number fewer than 20,000, with an ever-expanding number of distinct protein-coding isoforms. Here we review the status of the human gene catalogue and the efforts to complete it in recent years. Beside the ongoing annotation of protein-coding genes, their isoforms and pseudogenes, the invention of high-throughput RNA sequencing and other technological breakthroughs have led to a rapid growth in the number of reported non-coding RNA genes. For most of these non-coding RNAs, the functional relevance is currently unclear; we look at recent advances that offer paths forward to identifying their functions and towards eventually completing the human gene catalogue. Finally, we examine the need for a universal annotation standard that includes all medically significant genes and maintains their relationships with different reference genomes for the use of the human gene catalogue in clinical settings.
- Published
- 2023
- Full Text
- View/download PDF
7. Joint Distribution of Distance and Angles in Finite Wireless Networks
- Author
-
Martin-Vega, Francisco J., Gomez, Gerardo, Morales-Jimenez, David, Lopez-Martinez, F. Javier, and Aguayo-Torres, Mari Carmen
- Abstract
Directional beamforming will play a paramount role in 5G and beyond networks to combat the higher path losses incurred at millimeter wave bands. Appropriate modeling and analysis of the angles and distances between transmitters and receivers in these networks are thus essential to understand performance and limiting factors. Most existing literature considers either infinite and uniform networks, where nodes are drawn according to a Poisson point process, or finite networks with the reference receiver placed at the origin of a disk. Under either of these assumptions, the distance and azimuth angle between transmitter and receiver are independent, and the angle follows a uniform distribution between 0 and
. Here, we consider a more realistic case of finite networks where the reference node is placed at any arbitrary location. We obtain the joint distribution between the distance and azimuth angle and demonstrate that these random variables do exhibit certain correlation, which depends on the shape of the region and the location of the reference node. To conduct the analysis, we present a general mathematical framework that is specialized to exemplify the case of a rectangular region. We also derive the statistics for the 3D case where, considering antenna heights, the joint distribution of distance, azimuth, and zenith angles is obtained. Finally, we describe some immediate applications of the present work, including the design of analog codebooks, wireless routing algorithms, and the analysis of directional beamforming, which is illustrated by analyzing the coverage probability of an indoor scenario considering misaligned beams.$2\pi$ - Published
- 2023
- Full Text
- View/download PDF
8. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
- Author
-
Khanlari, Mahsa, Mo, Huan, Kim, Do Hwan, Sakhdari, Ali, Young, Ken H., Jain, Preetesh, Wang, Michael, Li, Shaoying, Kanagal-Shamanna, Rashmi, Miranda, Roberto N., Vega, Francisco, Medeiros, L. Jeffrey, and Ok, Chi Young
- Abstract
The blastoid (B) and pleomorphic (P) variants of mantle cell lymphoma (MCL) are associated with aggressive clinical behavior. In this study, we collected 102 cases of B-MCL and P-MCL from untreated patients. We reviewed clinical data, analyzed morphologic features using an image analysis tool (ImageJ) and we assessed mutational and gene expression profiles. The chromatin pattern of lymphoma cells was assessed quantitatively by the pixel value. Cases of B-MCL showed a greater median pixel value with lower variation compared with P-MCL, indicating a homogeneously euchromatin-rich pattern in B-MCL. In addition, the Feret diameter of the nuclei was significantly smaller (median 6.92 vs. 8.49 µm per nucleus, P<0.001) and had a lesser degree of variation in B-MCL compared with P-MCL, indicating that B-MCL cells have smaller cells with a more monomorphic appearance. B-MCL showed a significantly higher median Ki-67 proliferation rate (60% vs. 40%, P=0.003), and affected patients had poorer overall survival compared with those with P-MCL (median overall survival: 3.1 vs. 8.8 y, respectively, P=0.038). NOTCH1mutation was significantly more frequent in B-MCL compared with P-MCL (33% and 0%, respectively, P=0.004). Gene expression profiling showed 14 genes overexpressed in B-MCL cases and gene set enrichment assay for the overexpressed genes showed significant enrichment in the cell cycle and mitotic transition pathways. We also report a subset of MCL cases that has blastoid chromatin but a higher degree of pleomorphism in nuclear size and shape, designated here as hybrid MCL. Hybrid MCL cases had a similar Ki-67 proliferation rate, mutation profile, and clinical outcome to B-MCL and distinct from P-MCL. In summary, these data suggest biological differences between B-MCL and P-MCL cases justifying their separate designation when possible.
- Published
- 2023
- Full Text
- View/download PDF
9. Teaching Programming in the 21stCentury
- Author
-
de Vega, Francisco Fernández
- Abstract
ABSTRACTAlthough the teaching of programming has evolved over 50 years, all methodologies rely on a simple structure that was born a long time ago: the loop, shared by all high-level programming languages, and the preferred choice for any repetitive task programmers face. We analyze here how “loops” skew the way programmers solve problems, and prevent them from taking advantage of the available parallel/distributed computing architectures. To do so, we state our initial hypothesis: eliminating loops will allow a more natural parallel programming approach. The idea is to mimic a common practice today that was established in the past for a different purpose: prohibiting goto statements to improve code maintainability. This paper describes a new computer programming teaching strategy that we tested for 7 years and provides evidence on how loop prohibition, in the context of Functional Programming, makes students aware of data dependencies and produces 21st-century programmers who benefit from widely available parallel architectures.
- Published
- 2023
- Full Text
- View/download PDF
10. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
- Author
-
Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, and Westin, Jason R.
- Abstract
Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified regimens replacing R with obinutuzumab (O) or adding lenalidomide (L) did not result in improved outcomes; however, L and O together may enhance natural killer-cell mediated antibody-dependent cellular toxicity when paired with CHOP. Here, we report on a phase 1b/2 study of 53 patients with newly diagnosed DLBCL who received 6 cycles of LO-CHOP. The end of treatment overall and complete response rates of the 50 evaluable patients were 98% and 90%, respectively. After a median follow-up of 4.5 years, the 4-year progression free and overall survival rates were 87.4% and 91.3%, respectively. Grade 3 to 4 adverse events were experienced by 70% of patients, including neutropenia (38%), thrombocytopenia (17%), fatigue (13%), and neutropenic fever (13%). Of the 33 patients profiled with circulating tumor DNA (ctDNA) sequencing, 31 (94%) had detectable pretreatment ctDNA with cancer personalized profiling by deep sequencing, 24 (73%) were classifiable by the LymphGen classifier, and 15/20 (75%) and 12/17 (71%) patients achieved early and major molecular responses after 1 and 2 cycles, respectively. Using phased variant enrichment and detection sequencing, 16/18 evaluable patients (89%) showed no detectable ctDNA after at least 5 cycles of LO-CHOP. LO-CHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA. This trial has been registered at www.clinicaltrials.gov as NCT02529852.
- Published
- 2023
- Full Text
- View/download PDF
11. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
- Author
-
Karasaki, Takahiro, Moore, David A., Veeriah, Selvaraju, Naceur-Lombardelli, Cristina, Toncheva, Antonia, Magno, Neil, Ward, Sophia, Bakir, Maise Al, Watkins, Thomas B. K., Grigoriadis, Kristiana, Huebner, Ariana, Hill, Mark S., Frankell, Alexander M., Abbosh, Christopher, Puttick, Clare, Zhai, Haoran, Gimeno-Valiente, Francisco, Saghafinia, Sadegh, Kanu, Nnennaya, Dietzen, Michelle, Pich, Oriol, Lim, Emilia L., Martínez-Ruiz, Carlos, Black, James R. M., Biswas, Dhruva, Campbell, Brittany B., Lee, Claudia, Colliver, Emma, Enfield, Katey S. S., Hessey, Sonya, Hiley, Crispin T., Zaccaria, Simone, Litchfield, Kevin, Birkbak, Nicolai J., Cadieux, Elizabeth Larose, Demeulemeester, Jonas, Van Loo, Peter, Adusumilli, Prasad S., Tan, Kay See, Cheema, Waseem, Sanchez-Vega, Francisco, Jones, David R., Rekhtman, Natasha, Travis, William D., Hackshaw, Allan, Marafioti, Teresa, Salgado, Roberto, Le Quesne, John, Nicholson, Andrew G., McGranahan, Nicholas, Swanton, Charles, and Jamal-Hanjani, Mariam
- Abstract
Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions, were integrated with detailed whole-tumor and regional histopathological analysis. Tumors with predominantly high-grade patterns showed increased chromosomal complexity, with higher burden of loss of heterozygosity and subclonal somatic copy number alterations. Individual regions in predominantly high-grade pattern tumors exhibited higher proliferation and lower clonal diversity, potentially reflecting large recent subclonal expansions. Co-occurrence of truncal loss of chromosomes 3p and 3q was enriched in predominantly low-/mid-grade tumors, while purely undifferentiated solid-pattern tumors had a higher frequency of truncal arm or focal 3q gains and SMARCA4gene alterations compared with mixed-pattern tumors with a solid component, suggesting distinct evolutionary trajectories. Clonal evolution analysis revealed that tumors tend to evolve toward higher-grade patterns. The presence of micropapillary pattern and ‘tumor spread through air spaces’ were associated with intrathoracic recurrence, in contrast to the presence of solid/cribriform patterns, necrosis and preoperative circulating tumor DNA detection, which were associated with extra-thoracic recurrence. These data provide insights into the relationship between LUAD morphology, the underlying evolutionary genomic landscape, and clinical and anatomical relapse risk.
- Published
- 2023
- Full Text
- View/download PDF
12. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
- Author
-
Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D., de Oliveira Araujo, Iguaracyra Barreto, Berti, Emilio, Bhagat, Govind, Borges, Anita Maria, Boyer, Daniel, Calaminici, Mariarita, Chadburn, Amy, Chan, John K. C., Cheuk, Wah, Chng, Wee-Joo, Choi, John K., Chuang, Shih-Sung, Coupland, Sarah E., Czader, Magdalena, Dave, Sandeep S., de Jong, Daphne, Di Napoli, Arianna, Du, Ming-Qing, Elenitoba-Johnson, Kojo S., Ferry, Judith, Geyer, Julia, Gratzinger, Dita, Guitart, Joan, Gujral, Sumeet, Harris, Marian, Harrison, Christine J., Hartmann, Sylvia, Hochhaus, Andreas, Jansen, Patty M., Karube, Kennosuke, Kempf, Werner, Khoury, Joseph, Kimura, Hiroshi, Klapper, Wolfram, Kovach, Alexandra E., Kumar, Shaji, Lazar, Alexander J., Lazzi, Stefano, Leoncini, Lorenzo, Leung, Nelson, Leventaki, Vasiliki, Li, Xiao-Qiu, Lim, Megan S., Liu, Wei-Ping, Louissaint, Abner, Marcogliese, Andrea, Medeiros, L. Jeffrey, Michal, Michael, Miranda, Roberto N., Mitteldorf, Christina, Montes-Moreno, Santiago, Morice, William, Nardi, Valentina, Naresh, Kikkeri N., Natkunam, Yasodha, Ng, Siok-Bian, Oschlies, Ilske, Ott, German, Parrens, Marie, Pulitzer, Melissa, Rajkumar, S. Vincent, Rawstron, Andrew C., Rech, Karen, Rosenwald, Andreas, Said, Jonathan, Sarkozy, Clémentine, Sayed, Shahin, Saygin, Caner, Schuh, Anna, Sewell, William, Siebert, Reiner, Sohani, Aliyah R., Suzuki, Ritsuro, Tooze, Reuben, Traverse-Glehen, Alexandra, Vega, Francisco, Vergier, Beatrice, Wechalekar, Ashutosh D., Wood, Brent, Xerri, Luc, and Xiao, Wenbin
- Published
- 2023
- Full Text
- View/download PDF
13. Latency Fairness Optimization on Wireless Networks Through Deep Reinforcement Learning
- Author
-
Lopez-Sanchez, Maria, Villena-Rodriguez, Alejandro, Gomez, Gerardo, Martin-Vega, Francisco J., and Aguayo-Torres, Mari Carmen
- Abstract
In this paper, we propose a novel deep reinforcement learning (DRL) framework to maximize user fairness in terms of delay. To this end, we devise a new version of the modified largest weighted delay first (M-LWDF) algorithm, called
-M-LWDF, aiming to fulfill an appropriate balance between user fairness and average delay. This balance is defined as a feasible region on the cumulative distribution function (CDF) of the user delay that allows identifying unfair states, feasible-fair states, and over-fair states. Simulation results reveal that our proposed framework outperforms traditional resource allocation techniques in terms of latency fairness and average delay.$\beta$ - Published
- 2023
- Full Text
- View/download PDF
14. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms
- Author
-
Fang, Hong, Khoury, Joseph D., Torres-Cabala, Carlos A., Ng, Siok Bian, Xu, Jie, El Hussein, Siba, Hu, Shimin, Vega, Francisco, Li, Shaoying, Tang, Zhenya, Tang, Guilin, Medeiros, L. Jeffrey, and Wang, Wei
- Abstract
BCL11B is an essential transcription factor for T-cell lineage commitment and differentiation, and its dysregulation has been shown to be associated with T-cell tumourigenesis. In this study, we investigated BCL11B expression by immunohistochemical analysis in 120 cases of mature T-cell lymphoma, 34 B-cell lymphomas, 11 NK-cell neoplasms and 17 reactive cutaneous conditions. All cases of mycosis fungoides (n=23), primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (n=8) and T-prolymphocytic leukaemia (n=6) were positive for BCL11B and the staining intensity was higher than that of reactive T-cells. Fourteen of 15 (93%) cases of angioimmunoblastic T-cell lymphoma, 10 of 12 (83%) T-large granular lymphocytic leukaemia and 14 of 20 (70%) peripheral T-cell lymphoma, not otherwise specified, were also positive for BCL11B with an intensity comparable to reactive T-cells. Other T-cell neoplasms were uncommonly positive including one of three (33%) cases of primary cutaneous gamma delta T-cell lymphoma, one of four (25%) cases of subcutaneous panniculitis-like T-cell lymphoma, one of four (25%) cases of hepatosplenic T-cell lymphoma, and one of 20 (5%) cases of anaplastic large cell lymphoma (8 ALK-positive, 12 ALK-negative). T-cells in reactive cutaneous infiltrates were also positive for BCL11B, but staining intensity was much weaker than in mycosis fungoides. All NK-cell (n=11) and B-cell neoplasms (n=34) were negative for BCL11B. In conclusion, BCL11B shows a distinct expression pattern in various T-cell neoplasms. BCL11B appears to have utility as another T-cell marker and may be useful in the differential diagnosis of lymphoid neoplasms.
- Published
- 2022
- Full Text
- View/download PDF
15. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage
- Author
-
Latchmansingh, Kerri-Ann, Wang, Xiaoqiong, Verdun, Ramiro E., Marques-Piubelli, Mario L., Vega, Francisco, You, M. James, Chapman, Jennifer, and Lossos, Izidore S.
- Abstract
T- lymphoblastic leukemia/lymphoma (T-LL) is an aggressive malignancy of immature T-cells with poor overall survival (OS) and in need of new therapies. LIM-domain only 2 (LMO2) is a critical regulator of hematopoietic cell development that can be overexpressed in T-LL due to chromosomal abnormalities. Deregulated LMO2 expression contributes to T-LL development by inducing block of T-cell differentiation and continuous thymocyte self-renewal. However, LMO2 expression and its biologic significance in T-LL remain largely unknown. We analyzed LMO2 expression in 100 initial and follow-up biopsies of T-LL from 67 patients, including 31 (46%) early precursor T-cell (ETP)-ALL, 26 (39%) cortical and 10 (15%) medullary type. LMO2 expression was present in 50 (74.6%) initial biopsies with an average of 87% positive tumor cells (range 30–100%). LMO2 expression in ETP, medullary and cortical T-LLs was not statistically different. In patients with biopsies after initial therapy, LMO2 expression was stable. LMO2 expression was associated with longer OS (p= 0.048) regardless of T-lymphoblast stage or other clinicopathologic features. These findings indicate that LMO2 is a promising new prognostic marker that could predict patients' outcomes and potentially be targeted for novel chemotherapy, i.e. PARP1/2 inhibitors, which have been shown to enhance chemotherapy sensitivity in LMO2 expressing diffuse large B cell lymphoma (DLBCL) tumors by decreasing DNA repair efficiency.
- Published
- 2022
- Full Text
- View/download PDF
16. Nodular Lymphocyte–predominant Hodgkin Lymphoma With Nodular Sclerosis
- Author
-
El Hussein, Siba, Wang, Xiaoqiong, Fang, Hong, Jelloul, Fatima Zahra, Wang, Wei, Loghavi, Sanam, Vega, Francisco, Miranda, Roberto N., Muzzafar, Tariq, Manning, John T., Khoury, Joseph D., Burack, W. Richard, Evans, Andrew G., and Medeiros, L. Jeffrey
- Abstract
Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) with unusual features, including some that can overlap morphologically with classic Hodgkin lymphoma (CHL), have been described. Herein, we describe 12 cases of NLPHL with fibrous bands and capsular fibrosis resembling, in part, nodular sclerosis (NS) CHL. Seven of 12 cases harbored Reed-Sternberg–like cells, further suggestive of CHL, but all cases lacked associated eosinophils and/or plasma cells in the background. In this cohort, all cases had areas of so-called pattern D (nodular T-cell rich) as a sole component in 7 (58%) cases or as a hybrid pattern along with pattern E (diffuse T-cell/histiocyte-rich) in 5 (42%) cases. The immunophenotype of the large neoplastic cells in these cases supported their being lymphocyte predominant cells of NLPHL, positive for CD20, CD79a, and OCT2, and negative for CD15 and CD30. However, PAX5 was weak in 9 of 11 cases similar to Hodgkin/Reed-Sternberg cells in CHL. We conclude that some cases of NLPHL are associated with fibrous bands and capsular fibrosis and resemble, in part, NS CHL. In our experience, NLPHL with NS-like features occurs in 10% to 15% of cases of NLPHL and is associated with a variant pattern (D and/or E). In addition, all patients in this cohort were not treated before biopsy, suggesting that the prominent sclerosis in these cases is inherent to disease biology. Recognition of NLPHL with NS-like features further expands the morphologic spectrum of NLPHL and helps avoid potential misdiagnosis as CHL.
- Published
- 2022
- Full Text
- View/download PDF
17. A new genus of crab (Crustacea: Brachyura: Cyclodorippidae) from the lower Maastrichtian of NE Mexico
- Author
-
Vega, Francisco J. and Garassino, Alessandro
- Abstract
A new genus of crab from the lower Maastrichtian, Lower Siltstone Member of the Potrerillos Formation, Difunta Group, northeastern Mexico, is herein described based upon specimens collected from a single outcrop near the town of Paredón, Coahuila. The locality is nearby the San Marcos Fault, a geological feature that runs in a NW-SE direction and whose hydrothermalism may have influenced the preservation style of at least four crustacean species, whose cuticle is characterized by a red colour, which turns purple to yellow when weathered. New specimens resemble Sodakus mexicanus Vega, Feldmann & Villalobos-Hiriart, 1995; however, there are important differences compared with two other species of Sodakus from the Upper Cretaceous (Campanian) of South Dakota and New Mexico. The comparison of dorsal carapace morphology of the new specimens (including types of S. mexicanus), with Sodakus spp., indicate that these small crabs represent a new genus. Although no ventral parts were preserved, the sternum in the holotype of S. mexicanus, represents an opportunity to compare it with that of S. tatankayotankaensis Bishop, 1978. The rostrum preserved in the holotype of S. grethi Schweitzer, Feldmann, Kues & Bridge, 2017, from the Turonian of New Mexico, is different to the rostra observed in some of the new specimens. The cuticular ultrastructure of the new genus is illustrated. Three other crabs have been collected in association with the new specimens: the raninoid Bournelyreidus oaheensis (Bishop, 1978), Dakoticancer sp., and Costacopluma mexicana Vega & Perrilliat, 1989. Although we cannot present a definitively determine phylogenetic relationship of Paredonius n. gen., similarities with the Cyclodorippoidea are suggested.
- Published
- 2022
- Full Text
- View/download PDF
18. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
- Author
-
Chatila, Walid K., Kim, Jin K., Walch, Henry, Marco, Michael R., Chen, Chin-Tung, Wu, Fan, Omer, Dana M., Khalil, Danny N., Ganesh, Karuna, Qu, Xuan, Luthra, Anisha, Choi, Seo-Hyun, Ho, Yu-Jui, Kundra, Ritika, Groves, Katharine I., Chow, Oliver S., Cercek, Andrea, Weiser, Martin R., Widmar, Maria, Wei, Iris H., Pappou, Emmanouil P., Nash, Garrett M., Paty, Philip B., Shi, Qian, Vakiani, Efsevia, Duygu Selcuklu, S., Donoghue, Mark T. A., Solit, David B., Berger, Michael F., Shia, Jinru, Pelossof, Raphael, Romesser, Paul B., Yaeger, Rona, Smith, J. Joshua, Schultz, Nikolaus, Sanchez-Vega, Francisco, and Garcia-Aguilar, Julio
- Abstract
The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and surgery, but recent evidence suggests that patients with a complete response can avoid surgery permanently. To define correlates of response to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles of 738 untreated rectal cancers. APCmutations were less frequent in the lower than in the middle and upper rectum, which could explain the more aggressive behavior of distal tumors. No somatic alterations had significant associations with response to neoadjuvant therapy in a treatment-agnostic manner, but KRASmutations were associated with faster relapse in patients treated with neoadjuvant chemoradiation followed by consolidative chemotherapy. Overexpression of IGF2and L1CAMwas associated with decreased response to neoadjuvant therapy. RNA-sequencing estimates of immune infiltration identified a subset of microsatellite-stable immune hot tumors with increased response and prolonged disease-free survival.
- Published
- 2022
- Full Text
- View/download PDF
19. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- Author
-
Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D., Araujo, Iguaracyra Barreto de Oliveira, Berti, Emilio, Bhagat, Govind, Borges, Anita Maria, Boyer, Daniel, Calaminici, Mariarita, Chadburn, Amy, Chan, John K. C., Cheuk, Wah, Chng, Wee-Joo, Choi, John K., Chuang, Shih-Sung, Coupland, Sarah E., Czader, Magdalena, Dave, Sandeep S., de Jong, Daphne, Du, Ming-Qing, Elenitoba-Johnson, Kojo S., Ferry, Judith, Geyer, Julia, Gratzinger, Dita, Guitart, Joan, Gujral, Sumeet, Harris, Marian, Harrison, Christine J., Hartmann, Sylvia, Hochhaus, Andreas, Jansen, Patty M., Karube, Kennosuke, Kempf, Werner, Khoury, Joseph, Kimura, Hiroshi, Klapper, Wolfram, Kovach, Alexandra E., Kumar, Shaji, Lazar, Alexander J., Lazzi, Stefano, Leoncini, Lorenzo, Leung, Nelson, Leventaki, Vasiliki, Li, Xiao-Qiu, Lim, Megan S., Liu, Wei-Ping, Louissaint, Abner, Marcogliese, Andrea, Medeiros, L. Jeffrey, Michal, Michael, Miranda, Roberto N., Mitteldorf, Christina, Montes-Moreno, Santiago, Morice, William, Nardi, Valentina, Naresh, Kikkeri N., Natkunam, Yasodha, Ng, Siok-Bian, Oschlies, Ilske, Ott, German, Parrens, Marie, Pulitzer, Melissa, Rajkumar, S. Vincent, Rawstron, Andrew C., Rech, Karen, Rosenwald, Andreas, Said, Jonathan, Sarkozy, Clémentine, Sayed, Shahin, Saygin, Caner, Schuh, Anna, Sewell, William, Siebert, Reiner, Sohani, Aliyah R., Tooze, Reuben, Traverse-Glehen, Alexandra, Vega, Francisco, Vergier, Beatrice, Wechalekar, Ashutosh D., Wood, Brent, Xerri, Luc, and Xiao, Wenbin
- Abstract
We herein present an overview of the upcoming 5thedition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4thedition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5thedition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.
- Published
- 2022
- Full Text
- View/download PDF
20. SIRPα+macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
- Author
-
Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo
- Abstract
Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R2). Moreover, mechanisms of resistance to R2in FL remain unclear, with increased protumoral macrophages suspected as a major contributory culprit to this phenomenon. This retrospective study analyzed the outcome of patients with advanced-stage FL grade 1 to 3A who relapsed or progressed after frontline R2. A multiplex immunofluorescence macrophage panel, including CD47, CD14, CD68, CD115 (also known as colony-stimulating factor 1 receptor [CSF1R]), CD163, CD172a (also known as signal regulatory protein α [SIRPα]), and CD274 (also known as programmed cell death-ligand 1 [PDL1]), was used to stain tissue biopsy specimens collected before initiation of R2and at the time of progression. Among 156 patients with advanced-stage FL treated with frontline R2, 33 (21%) relapsed or progressed and required second-line therapy, after a median of 33 months (range, 1-122 months). Second-line therapy was chemoimmunotherapy in 16 (48%) patients and other therapy in 17 (52%). The overall response rate was 78%, and complete response rate was 72%. Median progression-free survival was significantly longer in patients who received chemoimmunotherapy compared with other therapy (99 vs 25 months; P= .004). Three macrophage populations were significantly increased in tissue samples collected at progression compared with before frontline treatment: CD68+CD115+(P= .02), CD68+CD115+CD172a+(P= .02), and CD68+CD163+CD172a+(P= .01). Chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2. Therapies targeting specific macrophage populations may yield novel approaches for improving outcomes with frontline R2.
- Published
- 2022
- Full Text
- View/download PDF
21. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
- Author
-
Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo
- Abstract
Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R2). Moreover, mechanisms of resistance to R2 in FL remain unclear, with increased protumoral macrophages suspected as a major contributory culprit to this phenomenon. This retrospective study analyzed the outcome of patients with advanced-stage FL grade 1 to 3A who relapsed or progressed after frontline R2. A multiplex immunofluorescence macrophage panel, including CD47, CD14, CD68, CD115 (also known as colony-stimulating factor 1 receptor [CSF1R]), CD163, CD172a (also known as signal regulatory protein α [SIRPα]), and CD274 (also known as programmed cell death-ligand 1 [PDL1]), was used to stain tissue biopsy specimens collected before initiation of R2 and at the time of progression. Among 156 patients with advanced-stage FL treated with frontline R2, 33 (21%) relapsed or progressed and required second-line therapy, after a median of 33 months (range, 1-122 months). Second-line therapy was chemoimmunotherapy in 16 (48%) patients and other therapy in 17 (52%). The overall response rate was 78%, and complete response rate was 72%. Median progression-free survival was significantly longer in patients who received chemoimmunotherapy compared with other therapy (99 vs 25 months; P = .004). Three macrophage populations were significantly increased in tissue samples collected at progression compared with before frontline treatment: CD68+CD115+ (P = .02), CD68+CD115+CD172a+ (P = .02), and CD68+CD163+CD172a+ (P = .01). Chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2. Therapies targeting specific macrophage populations may yield novel approaches for improving outcomes with frontline R2.
- Published
- 2022
- Full Text
- View/download PDF
22. Spain: Roles and missions of the Air Force
- Author
-
de la Vega, Francisco Jose Garcia
- Subjects
Spain. Air Force -- Equipment and supplies ,Spain. Air Force -- Management ,Military maneuvers -- Management ,Terrorism -- Safety and security measures ,Company business management ,Aerospace and defense industries ,Military and naval science - Abstract
Spain's national air space is under the permanent control and surveillance of the 'Ejercito del Aire' (Spanish Air Force, SPAF). Gen. Francisco Jose Garcia de la Vega, Chief of Staff of the Spanish Air Force, explains how the SPAF has responded to the changing war scenario by supplementing its concept of defense against external threats with the fight against terrorism, and the establishment of special security operations in relevant occasions.
- Published
- 2006
23. The linkage disequilibrium maps of three human chromosomes across four populations reflect their demographic history and a common underlying recombination pattern
- Author
-
De La Vega, Francisco M., Issac, Hadar, Collins, Andrew, Wogan, Lewis T., Ziegle, Janet S., Koehler, Ryan T., Laig-Webster, Marion, Yu Wang, Lippert, Ross A., Xiaoping Su, Halldorsson, Bjarni V., Scafe, Charles R., Stevens, Junko F., de The, Guy, Yi Zheng, Itakura, Mitsuo, Kalush, Francis, Hemken, Heinz G., Lily H. Xu, Xiaoqing You, Guegler, Karl J., Olson, Sheri J., Leinen, Kyle M., O'Brien, Stephen J., Spier, Eugene G., Hunkapiller, Michael W., Istrail, Sorin, and Clark, Andrew G.
- Subjects
Linkage (Genetics) -- Research ,Single nucleotide polymorphisms -- Research ,Human chromosomes -- Research ,Health - Abstract
A comparison of the patterns of linkage disequilibrium (LD) across four major human populations with a high-resolution single-nucleotide polymorphism (SNP) map covering almost the entire length of chromosomes 6, 21, and 22 is presented. Results are considered to have practical implications for the rational design and selection of SNPs for disease association studies.
- Published
- 2005
24. Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling
- Author
-
Agarwal, Nitin K., Kim, Chae-Hwa, Kunkalla, Kranthi, Vaghefi, Amineh, Sanchez, Sandra, Manuel, Samantha, Bilbao, Daniel, Vega, Francisco, and Landgraf, Ralf
- Abstract
The oncoprotein Smoothened (SMO), a Frizzled-class-G-protein-coupled receptor, is the central transducer of hedgehog (Hh) signaling. While canonical SMO signaling is best understood in the context of cilia, evidence suggests that SMO has other functions in cancer biology that are unrelated to canonical Hh signaling. Herein, we provided evidence that elevated levels of human SMO show a strong correlation with elevated levels of insulin-like growth factor 1 receptor (IGF1R) and reduced survival in diffuse large B-cell lymphoma (DLBCL). As an integral component of raft microdomains, SMO plays a fundamental role in maintaining the levels of IGF1R in lymphoma and breast cancer cells as well IGF1R-associated activation of protein kinase B (AKT). Silencing of SMOincreases lysosomal degradation and favors a localization of IGF1R to late endosomal compartments instead of early endosomal compartments from which much of the receptor would normally recycle. In addition, loss of SMO interferes with the lipid raft localization and retention of the remaining IGF1R and AKT, thereby disrupting the primary signaling context for IGF1R/AKT. This activity of SMO is independent of its canonical signaling and represents a novel and clinically relevant contribution to signaling by the highly oncogenic IGF1R/AKT signaling axis.
- Published
- 2022
- Full Text
- View/download PDF
25. Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma
- Author
-
Khanlari, Mahsa, Li, Shaoying, Miranda, Roberto N., Iyer, Swaminathan, Konoplev, Sergej, Lin, Pei, Yin, C. Cameron, Tang, Guilin, Qiu, Lianqun, Vega, Francisco, Medeiros, L. Jeffrey, and Xu, Jie
- Abstract
Several morphologic variants of ALK+ anaplastic large cell lymphoma (ALCL) are recognized. The small cell (SC) and lymphohistiocytic (LH) variants are reported to be associated with poorer outcome in children with ALK + ALCL. In this study of 102 adults with ALK + ALCL, there were 18 (18%) cases of SC and/or LH variants. Patients with SC/LH ALK + ALCL more often had peripheral blood involvement than patients with non-SC/LH neoplasms (60% vs 0%, p= 0.02). There were no other significant differences in clinical features between patients with SC/LH versus non-SC/LH ALK + ALCL. Compared with non-SC/LH cases of ALK + ALCL, neoplasms with SC/LH features were more often positive for CD2 (92% vs. 36%, p= 0.0007), CD3 (81% vs. 15%, p= 0.0001), CD7 (80% vs. 37%, p= 0.03), and CD8 (54% vs. 7%, p= 0.0006). There were no other significant differences in the immunophenotype between SC/LH and non-SC/LH ALK + ALCL cases. The initial chemotherapy regimens and the response rates were similar between patients with ALK + ALCL with SC/LH patterns versus those with non-SC/LH patterns. After a median follow-up of 30.8 months (range, 0.3–208 months), patients with high (>3) International Prognostic Index (IPI) scores had significantly shorter overall survival than patients with low (<3) IPI scores (p= 0.003). However, there was no significant difference in overall or progression-free survival between patients with SC/LH versus non-SC/LH ALK + ALCL (p= 0.99 and p= 0.94, respectively). We conclude that, in adults with ALK + ALCL, SC and LH variants are associated with peripheral blood involvement and a CD8 + immunophenotype with retention of T-cell markers (CD2, CD3, and CD7). However, in contrast with children with ALK + ALCL, SC and LH variants appear to have no impact on prognosis in adults with ALK + ALCL.
- Published
- 2022
- Full Text
- View/download PDF
26. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up
- Author
-
Vega, Francisco, Amador, Catalina, Chadburn, Amy, Hsi, Eric D., Slack, Graham, Medeiros, L. Jeffrey, and Feldman, Andrew L.
- Abstract
Peripheral T-cell lymphomas are a heterogeneous, and usually aggressive, group of mature T-cell neoplasms with overlapping clinical, morphologic and immunologic features. A large subset of these neoplasms remains unclassifiable with current diagnostic methods (“not otherwise specified”). Genetic profiling and other molecular tools have emerged as widely applied and transformative technologies for discerning the biology of lymphomas and other hematopoietic neoplasms. Although the application of these technologies to peripheral T-cell lymphomas has lagged behind B-cell lymphomas and other cancers, molecular profiling has provided novel prognostic and diagnostic markers as well as an opportunity to understand the biologic mechanisms involved in the pathogenesis of these neoplasms. Some biomarkers are more prevalent in specific T-cell lymphoma subsets and are being used currently in the diagnosis and/or risk stratification of patients with peripheral T-cell lymphomas. Other biomarkers, while promising, need to be validated in larger clinical studies. In this review, we present a summary of our current understanding of the molecular profiles of the major types of peripheral T-cell lymphoma. We particularly focus on the use of biomarkers, including those that can be detected by conventional immunohistochemical studies and those that contribute to the diagnosis, classification, or risk stratification of these neoplasms.
- Published
- 2022
- Full Text
- View/download PDF
27. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.
- Author
-
Nair, Ranjit, Prakash, Rishab, Dang, Anna, Gunther, Jillian R., Huen, Auris, Xu, Jie, Malpica Castillo, Luis Enrique, Torres Cabala, Carlos, Heberton, Meghan, Fang, Penny, Ahmed, Sairah, Miranda, Roberto N., Fayad, Luis, Steiner, Raphael, Lee, Hun Ju, Chihara, Dai, Jain, Preetesh, Srour, Samer A, Ramdial, Jeremy L, Nieto, Yago, Nastoupil, Loretta J., Pinnix, Chelsea C., Neelapu, Sattva S., Flowers, Christopher R., Medeiros, L. Jeffrey, Hosing, Chitra, Wang, Michael L., Dabaja, Bouthaina S., Vega, Francisco, Feng, Lei, and Iyer, Swaminathan Padmanabhan
- Published
- 2022
- Full Text
- View/download PDF
28. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
- Author
-
Agbedia, Owhofasa O., Prakash, Rishab, Xu, Jie, Becnel, Melody R., Nair, Ranjit, Steiner, Raphael E, Feng, Lei, Lee, Hun Ju, Strati, Paolo, Ahmed, Sairah, Parmar, Simrit, Nieto, Yago, Hosing, Chitra, Westin, Jason, Nastoupil, Loretta J., Vo, Ann, Samaniego, Felipe, Fowler, Nathan H., Saini, Neeraj, Khouri, Issa F., Im, Jin S., Fayad, Luis, Jain, Preetesh, Wang, Michael L., Miranda, Roberto N., Vega, Francisco, Medeiros, Jeffrey, Oki, Yasuhiro, Flowers, Christopher R., Neelapu, Sattva S., and Iyer, Swaminathan P.
- Published
- 2022
- Full Text
- View/download PDF
29. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
- Author
-
Nair, Ranjit, Ayers, Amy, Nastoupil, Loretta J., Gunther, Jillian R., Fayad, Luis, Fowler, Nathan H., Miranda, Roberto N., Hagemeister, Fredrick B., Lee, Hun Ju, Rodriguez, Maria Alma, Steiner, Raphael, Strati, Paolo, Nieto, Yago, Ramdial, Jeremy L., Chihara, Dai, Wang, Michael L., Malpica Castillo, Luis E, Saini, Neeraj, Jain, Preetesh, Pinnix, Chelsea C., Dabaja, Bouthaina S., Green, Michael R, Flowers, Christopher R., Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Vega, Francisco, Noorani, Mansoor, Ahmed, Sairah, Westin, Jason, Neelapu, Sattva S., Feng, Lei, and Iyer, Swaminathan Padmanabhan
- Published
- 2022
- Full Text
- View/download PDF
30. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
- Author
-
Jain, Preetesh, Ok, Chi Young, Fetooh, Ahmed, Kanagal-Shamanna, Rashmi, Jelloul, Fatima Zahra, Hill, Holly, Floyd, Kristen, Loghavi, Sanam, Zuo, Zhuang, Yin, C. Cameron, Routbort, Mark, Tang, Guilin, Ahmed, Sairah, Malpica Castillo, Luis Enrique, Siddiqui, Asiya, Chen, Wendy, Oriabure, Onyeka, Badillo, Maria, Steiner, Raphael E, Iyer, Swaminathan P., Lee, Hun Ju, Luthra, Rajyalakshmi, Vega, Francisco, Flowers, Christopher R., Medeiros, Jeffrey, Wang, Michael L., Patel, Keyur P., Fowler, Nathan H., and Nair, Ranjit
- Published
- 2022
- Full Text
- View/download PDF
31. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
- Author
-
Ruan, Jia, Larson, Melissa C., Chen, Zhengming, Bennani, N. Nora, Allen, Pamela B., Jaye, David L, Cohen, Jonathon B., Chihara, Dai, Vega, Francisco, Inghirami, Giorgio, Mou, Eric, Casulo, Carla, Mehta-Shah, Neha, Martin, Peter, Maurer, Matthew J., Kahl, Brad S., Lossos, Izidore S., Flowers, Christopher R., Cerhan, James R., and Feldman, Andrew L.
- Published
- 2022
- Full Text
- View/download PDF
32. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
- Author
-
Nze, Chijioke, Andersen, Clark R, Ayers, Amy, Westin, Jason, Wang, Michael L., Iyer, Swaminathan P., Ahmed, Sairah, Pinnix, Chelsea C., Vega, Francisco, McNeil, Lorna, Nguyen, Lynne, Nastoupil, Loretta J., and Flowers, Christopher R.
- Published
- 2022
- Full Text
- View/download PDF
33. Cutaneous/ Subcutaneous Involvement - an Immuneprivileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.
- Author
-
Nair, Ranjit, Prakash, Rishab, Dang, Anna, Gunther, Jillian R., Huen, Auris, Xu, Jie, Malpica Castillo, Luis Enrique, Torres Cabala, Carlos, Heberton, Meghan, Fang, Penny, Ahmed, Sairah, Miranda, Roberto N., Fayad, Luis, Steiner, Raphael, Lee, Hun Ju, Chihara, Dai, Jain, Preetesh, Srour, Samer A, Ramdial, Jeremy L, Nieto, Yago, Nastoupil, Loretta J., Pinnix, Chelsea C., Neelapu, Sattva S., Flowers, Christopher R., Medeiros, L. Jeffrey, Hosing, Chitra, Wang, Michael L., Dabaja, Bouthaina S., Vega, Francisco, Feng, Lei, and Iyer, Swaminathan Padmanabhan
- Published
- 2022
- Full Text
- View/download PDF
34. Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship
- Author
-
Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Sangiorgio, Valentina F.I., Ruiz-Cordero, Roberto, Vega, Francisco, Feldman, Andrew L., Chapman, Jennifer R., Clemens, Mark W., Hunt, Kelly K., Evans, Mark G., Khoo, Christine, Lade, Stephen, Silberman, Mark, Morkowski, Jerzy, Pina, Edward M., Mills, Daniel C., Bates, Christopher M., Magno, Winston B., Sohani, Aliyah R., Sieling, Beth A., O'Donoghue, Joseph M., Bacon, Chris M., Patani, Neill, Televantou, Despina, Turner, Suzanne D., Johnson, Laura, MacNeill, Fiona, Wotherspoon, Andrew C., Iyer, Swaminathan P., Malpica, Luis E., Patel, Keyur P., Xu, Jie, and Miranda, Roberto N.
- Abstract
Breast implant anaplastic large cell lymphoma (ALCL) is a T-cell neoplasm arising around textured breast implants that was recognized recently as a distinct entity by the World Health Organization. Rarely, other types of lymphoma have been reported in patients with breast implants, raising the possibility of a pathogenetic relationship between breast implants and other types of lymphoma. We report eight cases of Epstein–Barr virus (EBV)-positive large B-cell lymphoma associated with breast implants. One of these cases was invasive, and the other seven neoplasms were noninvasive and showed morphologic overlap with breast implant ALCL. All eight cases expressed B-cell markers, had a non-germinal center B-cell immunophenotype, and were EBV+ with a latency type III pattern of infection. We compared the noninvasive EBV+ large B-cell lymphoma cases with a cohort of breast implant ALCL cases matched for clinical and pathologic stage. The EBV+ large B-cell lymphoma cases more frequently showed a thicker capsule, and more often were associated with calcification and prominent lymphoid aggregates outside of the capsule. The EBV+ B-cell lymphoma cells were more often arranged within necrotic fibrinoid material in a layered pattern. We believe that this case series highlights many morphologic similarities between EBV+ large B-cell lymphoma and breast implant ALCL. The data presented suggest a pathogenetic role for breast implants (as well as EBV) in the pathogenesis of EBV+ large B-cell lymphoma. We also provide some histologic findings useful for distinguishing EBV+ large B-cell lymphoma from breast implant ALCL in this clinical setting.
- Published
- 2021
- Full Text
- View/download PDF
35. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
- Author
-
Martinez-Baquero, Diana, Sakhdari, Ali, Mo, Huan, Kim, Do Hwan, Kanagal-Shamanna, Rashmi, Li, Shaoying, Young, Ken H., O'Malley, Dennis P., Dogan, Ahmet, Jain, Preetesh, Wang, Michael L., McDonnell, Timothy J., Miranda, Roberto N., Vega, Francisco, Medeiros, L. Jeffrey, and Ok, Chi Young
- Abstract
Enhancer of zeste homolog 2 (EZH2) is a catalytic component of the polycomb repressive complex 2 (PRC2) which reduces gene expression via trimethylation of a lysine residue of histone 3 (H3K27me3). Expression of EZH2 has not been assessed systematically in mantle cell lymphoma (MCL). Expression of EZH2 was assessed by immunohistochemistry in 166 patients with MCL. We also assessed other PRC2 components and H3K27me3. Fifty-seven (38%) of MCL patients were positive for EZH2 using 40% cutoff. EZH2 expression was associated with aggressive histologic variants (65% vs. 29%, p< 0.001), high Ki-67 proliferation rate (median, 72% vs. 19%, p< 0.001), and p53 overexpression (43% vs. 2%, p< 0.001). EZH2 expression did not correlate with expression of other PRC2 components (EED and SUZ12), H3K27me3, MHC-I, and MHC-II. Patients with EZH2 expression (EZH2+) had a poorer overall survival (OS) compared with patients without EZH2 expression (EZH2−) (median OS: 3.9 years versus 9.4 years, respectively, p< 0.001). EZH2 expression also predicted a poorer prognosis in MCL patients with classic histology (median OS, 4.6 years for EZH2+ and 9.6 years for EZH2-negative, respectively, p< 0.001) as well as aggressive histology (median OS, 3.7 years for EZH2+ and 7.9 years for EZH2-negative, respectively, p= 0.046). However, EZH2 expression did not independently correlate with overall survival in a multivariate analysis. Gene expression analysis and pathway enrichment analysis demonstrated a significant enrichment in cell cycle and mitotic transition pathways in MCL with EZH2 expression. EZH2 expression detected by immunohistochemistry is present in 38% of MCL cases and it is associated with high proliferation rate, p53 overexpression, aggressive histologic variants, and poorer OS. Based on gene expression profiling data, EZH2 expression could potentiate cell cycle machinery in MCL. These data suggest that assessment of EZH2 expression could be useful to stratify MCL patients into low- and high-risk groups.
- Published
- 2021
- Full Text
- View/download PDF
36. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
- Author
-
Plaks, Vicki, Rossi, John M., Chou, Justin, Wang, Linghua, Poddar, Soumya, Han, Guangchun, Wang, Zixing, Kuang, Shao-Qing, Chu, Fuliang, Davis, Richard E., Vega, Francisco, Bashir, Zahid, Jacobson, Caron A., Locke, Frederick L., Reagan, Patrick M., Rodig, Scott J., Lekakis, Lazaros J., Flinn, Ian W., Miklos, David B., Bot, Adrian, and Neelapu, Sattva S.
- Published
- 2021
- Full Text
- View/download PDF
37. A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer
- Author
-
Kemeny, Nancy E., Chou, Joanne F., Capanu, Marinela, Chatila, Walid K., Shi, Hongyu, Sanchez-Vega, Francisco, Kingham, Thomas Peter, Connell, Louise Catherine, Jarnagin, William R., and D’Angelica, Michael I.
- Abstract
Supplemental Digital Content is available in the text
- Published
- 2021
- Full Text
- View/download PDF
38. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
- Author
-
Dunbar, Andrew, Bolton, Kelly L., Devlin, Sean M., Sanchez-Vega, Francisco, Gao, Jianjiong, Mones, Jodi V., Wills, Jonathan, Kelly, Daniel, Farina, Mirko, Cordner, Keith B., Park, Young, Kishore, Sirish, Juluru, Krishna, Iyengar, Neil M., Levine, Ross L., Zehir, Ahmet, Park, Wungki, Khorana, Alok A., Soff, Gerald A., and Mantha, Simon
- Abstract
Venous thromboembolism (VTE) associated with cancer (CAT) is a well-described complication of cancer and a leading cause of death in patients with cancer. The purpose of this study was to assess potential associations of molecular signatures with CAT, including tumor-specific mutations and the presence of clonal hematopoiesis. We analyzed deep-coverage targeted DNA-sequencing data of >14 000 solid tumor samples using the Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets platform to identify somatic alterations associated with VTE. End point was defined as the first instance of cancer-associated pulmonary embolism and/or proximal/distal lower extremity deep vein thrombosis. Cause-specific Cox proportional hazards regression was used, adjusting for pertinent clinical covariates. Of 11 695 evaluable individuals, 72% had metastatic disease at time of analysis. Tumor-specific mutations in KRAS (hazard ratio [HR], 1.34; 95% confidence interval (CI), 1.09-1.64; adjusted P = .08), STK11 (HR, 2.12; 95% CI, 1.55-2.89; adjusted P < .001), KEAP1 (HR, 1.84; 95% CI, 1.21-2.79; adjusted P = .07), CTNNB1 (HR, 1.73; 95% CI, 1.15-2.60; adjusted P = .09), CDKN2B (HR, 1.45; 95% CI, 1.13-1.85; adjusted P = .07), and MET (HR, 1.83; 95% CI, 1.15-2.92; adjusted P = .09) were associated with a significantly increased risk of CAT independent of tumor type. Mutations in SETD2 were associated with a decreased risk of CAT (HR, 0.35; 95% CI, 0.16-0.79; adjusted P = .09). The presence of clonal hematopoiesis was not associated with an increased VTE rate. This is the first large-scale analysis to elucidate tumor-specific genomic events associated with CAT. Somatic tumor mutations of STK11, KRAS, CTNNB1, KEAP1, CDKN2B, and MET were associated with an increased risk of VTE in patients with solid tumors. Further analysis is needed to validate these findings and identify additional molecular signatures unique to individual tumor types.
- Published
- 2021
- Full Text
- View/download PDF
39. Targeted based therapy in nodal T-cell lymphomas
- Author
-
Chihara, Dai, Miljkovic, Milos, Iyer, Swaminathan P., and Vega, Francisco
- Abstract
T-cell lymphomas (TCL) are a group of biologically and clinically heterogenous neoplasms derived from mature T lymphocytes. Recent findings in biology have advanced the classification of these neoplasms; however, clinical investigations based on biologic features have yet to be designed. Two biomarker-driven treatments for TCL are promising: brentuximab vedotin (BV) in combination with chemotherapy or as monotherapy is the standard treatment for newly diagnosed CD30-positive TCL and relapsed/refractory anaplastic large cell lymphoma (ALCL), while ALK inhibitors have induced responses in ALK+ ALCLs. Common genetic alterations in TCL, such as aberrations in PI3K/mTOR, JAK/STAT, and epigenetic regulators are also targetable by pathway inhibitors and HDAC/DNMT inhibitors; however, responses to these treatments as monotherapy are neither satisfactory nor durable, even in patients pre-stratified by several biomarkers. Additional work is needed to extend biology/biomarker-driven treatment in these neoplasms. As T-cell lymphomagenesis is multistep and multifactorial, trials are ongoing to evaluate combination treatments. The focus of this article is to summarize the status and the current role of targeted-based therapy in nodal TCL.
- Published
- 2021
- Full Text
- View/download PDF
40. Risk factors and outcomes associated with vancomycin-resistant Enterococcus faeciumand ampicillin-resistant Enterococcus faecalisbacteraemia: A 10-year study in a tertiary-care centre in Mexico City
- Author
-
López-Luis, Bruno Ali, Sifuentes-Osornio, José, Lambraño-Castillo, Darwin, Ortiz-Brizuela, Edgar, Ramírez-Fontes, Andrea, Tovar-Calderón, Yanet Estrella, Leal-Vega, Francisco Javier, Bobadilla-del-Valle, Miriam, and Ponce-de-León, Alfredo
- Abstract
•Vancomycin-resistant Enterococcus faeciumis associated with broad healthcare exposure.•Vancomycin-resistant E. faeciumis not only related to prior antibiotic exposure.•Cancer treatment and APACHE II score were associated with mortality in E. faeciumbacteraemia.•Ampicillin-resistant Enterococcus faecalisaccounts for up to 5% of bacteraemias.
- Published
- 2021
- Full Text
- View/download PDF
41. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7− CD4+ T‐cells
- Author
-
Lyapichev, Kirill A., Bah, Ismael, Huen, Auris, Duvic, Madeleine, Routbort, Mark J., Wang, Wei, Jorgensen, Jeffrey L., Medeiros, L. Jeffrey, Vega, Francisco, Craig, Fiona E., and Wang, Sa A.
- Abstract
Blood involvement by mycosis fungoides (MF)/Sézary syndrome (SS) influences prognosis and therapeutic decisions. MF/SS blood stage is currently determined by absolute CD4 + CD26− or CD4 + CD7‐cell counts, which quantification method may overestimate MF/SS by including CD26− or CD7− normal CD4+ T‐cells, or underestimate disease burden when MF/SS cells show incomplete loss of CD26 and/or CD7. Recently, through the standardization effort led by the International Clinical Cytometry Society (ICCS), recommendation was made to quantify MF/SS by enumerating immunophenotypically aberrant CD4+ T‐cells, rather than CD26− or CD7− in isolation. We compared these two quantitation methods in 309 MF/SS patients who had blood samples analyzed by flow cytometry immunophenotyping (FCI) over a 1‐year period. Using the European Organization of Research and Treatment of Cancer (EORTC)/International Society for Cutaneous Lymphomas (ISCL) criteria, 221 (71.5%) patients had a blood stage corresponding to B0, 57 (18.4%) to B1, and 31 (10%) to B2. By FCI analysis, a total of 62 patients (20.0%) were found positive for MF/SS. Among EORTC B0 patients, 11/221 (5%) were positive by FCI (false negatives), and among EORTC Stage B1 patients, 35/57 (61%) were negative by FCI (false positives). Regarding patients positive for MF/SS cells by FCI, there was an overall excellent correlation (r= .999, p< .001) between the EORTC/ISCL method and FCI method; however, four (6.5%) patients would have an altered B stage between B0 and B1. The MF/SS cell quantification method using immunophenotypic aberrancies, as recommended by the ICCS, allows to distinguish MF/SS cells from background benign T‐cells and enables for more accurate staging, especially among patients currently being considered to have B0 and B1 stage diseases.
- Published
- 2021
- Full Text
- View/download PDF
42. Prevalencia de la enfermedad renal crónica y factores asociados en la población asistida en atención primaria de España: resultados del estudio IBERICAN
- Author
-
Llisterri, José Luis, Micó-Pérez, Rafael Manuel, Velilla-Zancada, Sonsoles, Rodríguez-Roca, Gustavo Cristóbal, Prieto-Díaz, Miguel Ángel, Martín-Sánchez, Vicente, Barquilla, Alfonso, Polo-García, José, Segura-Fragoso, Antonio, Cinza-Sanjurjo, Sergio, García, Alfonso Barquilla, Rodríguez, Ángel Díaz, Cervantes, Carlos Escobar, Moreno, Francisco Javier Alonso, Roca, Gustavo Cristóbal Rodríguez, Martín, Jesús Vergara, Caro, José Luis Llisterri, Badimón, Juan José, García, José Polo, Padial, Luis Rodríguez, Prieto, Miguel Ángel, Pérez, Rafael Vidal, Sanjurjo, Sergio Cinza, Jiménez, Sonia Miravet, Zancada, Sonsoles Velilla, Téllez, Antonio López, de Los Ángeles Ortega Osuna, Maria, Cid, Cristóbal Prieto, Fajardo, María José Hidalgo, Serna, José Lorente, Requena, Ángel Domínguez, Cañizares, Ricardo Alberola, Peña, Manuel Ruiz, Collado, Filomena Herrero, Vázquez, Marcela Montes, Garrido, Rafael Ángel Carrascal, Lozano, María Reyes Herrera, Oliva, Beatriz Ortiz, Anguita, Francisco José, Ibáñez, Carmen Pérez, Rodríguez, Carlos Alberto Cabrera, Rodríguez, María José Cruz, Ruiz, Sandra Bonilla, González, Rocío Reina, Sánchez, Salomé Abad, Martínez, Inmaculada Santana, Jordán, Rafael Sánchez, Navas-Parejo, Juan María Ramos, Torres, José Manuel Ramírez, Poveda, José María Beltrán, Benayas, María Adoración de Cruz, Gil, Carmen Fernandez, Alcaine, Jon Iñaki Esturo, Quintero, Antonio Mora, Cepas, Fernando Leiva, Martín, José Luis Carrasco, Criado, Emilio García, Blanco, Mercedes Vázquez, Ortiz, Isabel Mora, Mendoza, Leovigildo Ginel, Rodríguez, Juan Carlos Aguirre, Rodríguez, Esperanza María Romero, Vázquez, José Acevedo, Ballesteros, Juan Gabriel García, Lara, María de La Paz Fernández, Moreno, Patricia Agüera, Maturana, Eduardo Paños, Expósito, Juan Manuel Ignacio, Peñas, Noelia Carrillo, Faya, Carmen María Abad, Duque, Ana Marina Almagro, Camisón, Rubén Torrescusa, Polo, Paloma Menéndez, García, Marina Peña, Fernández, Cristina López, Torres, Ascensión Estepa, Jansen, Miguel Gutiérrez, González, Esperanza Loizaga, Matarin, Lisardo García, Luna, Enrique José Gamero de, Rivero, Javier Benítez, Gómez González, María José, Montes, Carmen Gómez, Calvo, Eva Trillo, Calvo, Concepción Bayod, Natividad, Susana Larripa de La, Lambea, Germán Grasa, Marín, Emilio Jiménez, Gonzalvo, Ana Cristina Navarro, Martínez Barseló, Antonio Pablo, León, Irene Peña, Fernández, E. Lidia Gutiérrez, Mantecón, Fernando Andrés, Garrido, Ana Belén García, Escalante, Asunción Velez, Rentería, Luisa Alonso, Jiménez, Jesús Sainz, Alles, Guillermo Pombo, Garrote, Juan Antonio Divison, Sotodosos, Pedro Martínez, Fuster, Juan Antonio Vivancos, Palencia, María García, Moraleda, José Ambrosio Torres, Ballesteros, Sara González, Adrados, Ana Carmen Gil, Cabrera, Antonio González, Fernández, Miguel Ángel Babiano, García, Guillermo Rico, Criado-Álvarez, Juan José, Moreno, Pilar Torres, Aguirregaviria, Francisco Javier Arribas, Martínez, Alicia Sahuquillo, Béjar, Lourdes María Santos, Peralta, Miguel Laborda, Castro, Raúl Piedra, Altozano, Carlos Santos, Polo, Lucía González-Tarrio, Maresca, Pedro Valiente, Santana, Reinilda Mota, Ledesma, Noemi Elizabeth Terrero, Espada, Noelia Garrido, Moreno, Francisco Javier Alonso, Calvi, Gabriela Delia Rosa Zambrana, Montero, Juan Lorenzo Gutiérrez, Gil, Juan Ignacio López, Ortega, María Dolores Fernández, Roncal, Miren Elizari, Serrano, María Ascensión López, Fuente, Nuria Esther Adrián de La, Larrea, Belén Angulo Fdez. de, Fernández, Naiara Cubelos, Gómez, Guiomar Luz Ferreiro, Rodríguez, Diana Gómez, Tuñón, Sonia María Andrés, González, María Ajenjo, Olea, Serafín de Abajo, Regueras, Juan José León, Nieto, César Manuel Gallego, Mallada, Delio Vázquez, García, Maria de La O Gutiérrez, Rodríguez, Pablo Baz, García, José Ignacio Ferradal, Martínez, Blanca Delia de Román, Pérez, Ana Arconada, Atoui, Omar Mahmoud, Bayón, Álvaro Morán, Olmo, María Teresa Armenteros del, Herreros, Fco. Javier García-Norro, Rodríguez, Enrique Méndez, Pineda, Diana María Narganes, Ainaga, Verónica Ortiz, Guevara, Milagros Sonlei Sánchez, Ferreiro, Laura Villota, Grande, M. Teresa Grande, Gracía, Francisco Vicente Martínez, García, María Dolores Moriano, Muñoz, Beatriz Jiménez, Marcelino, Gemma Rovira, Valverde, Diana Elizabeth Fernández, Bernadó, Roser Rodó, Lupiáñez, María Teresa Ortiz, Najih, Najlaa, Parra, José María Diéguez, Acebo, María Rosa Benedicto, Vicien, Mari Luz Bravo, Estella, Alberto Ramón León, Gómez, Juan Antonio Muñoz, Muntané, Alicia Mostazo, Abarca, Isabel Ortega, Fargas, Anna Gasol, Escudero, Brenda Elizabeth Riesgo, Riesgo, Susana Elizabeth, Castellvi, Edgar Zaballos, Sagarra, Celia Cols, Fernández, Marta Herranz, Presas, Josep Alins, Pérez, Idaira Damas, García, Rosa M. Alcolea, Collado, Inés Monte, Martínez, Roberto Genique, Villanueva, María José Guasch, Martínez, Teresa Rama, Pena, Lucio Pinto, Royo, Josefa María Panisello, Gil, Inés Gil, Montero, Alberto Calderón, Gómez, María del Mar Zamora, Cebrián, Elena Alarcón, Acin, María José Piñero, Sacristán, Celia Pecharromán, Vicente, M. Soledad Mayayo, Unanua, María Paz Pérez, Henrich, Nuria Marañón, Monreal, Saray Gómez, Pedro, Sonia Redondo de, Pozo, Blanca Sanz, Martínez, Irene Moreno, Uriarte, Beatriz López, Velasco, Carmelina Sanz, Aguirre, Amaya Gárriz, Teijido, Montserrat Rivera, Jaén, Germán Reviriego, Pascual-Salcedo, José Ignacio Aza, Gallego, Josefa Vázquez, Rodilla, Julia Caballer, Herrera, Aida, Martínez, Ezequiel Arranz, Calvo, Ana María Gómez, Oliva, Paula Morán, Béjar, María Milagros González, Hitos, Julio Antonio Heras, Vallejo, Olga García, Vargas, Manuel de Jesús Frías, Boguerin, María Jesús Castillejo, Lerin, Aurora García, Tablado, Miguel Ángel María, García, Elena Concepción García, Acero, Leticia de Miguel, Oñate, Carmen Zárate, Apoita, Aránzazu Barranco, Belloso, María Ester Montes, Velasco, Ana María Huertas, Jiménez, Rafael Sáez, Pascual, Julia Natividad García, Zuluaga, María Clemencia Zuluaga, Perez, María Cruz Díez, García, Antonio Ruiz, Jelsbak, Cristina Murillo, Oria, Virginia Lasso, Gamarra, Amelia González, Fuster, Vicente Pascual, Bort, María Dolores Aicart, Gómez, Natividad Vázquez, Gasco, Carlos Lluna, Barber, Teresa Amoros, Cano, Pedro Antonio Medina, Moncho, Miguel Monteagudo, Muñoz, María Jesús Larré, Hernández, Raquel Navarro, Egea, Francisco José Martínez, Tramontano, Antonio, Royo, Marta Ferrer, Saura, Belén Persiva, Torres, Juan A. Contreras, Moliner, José María Tirado, Penalba, Alejandro Salanova, Alberola, Ariadna Cucó, Ros, Fernando María Navarro I., Llicer, Enrique Beltrán, Novás, Ana Seoane, Valls, Inmaculada Martín, Mahiques, Gracia Verdú, Forcada, Enrique Peña, Gómez, Nieves Aguilar, García, Francisco Javier Sanz, Bueso, M. Dolores Paradís, Romero, María Eugenia Alegre, Camus, Antonio Francés, Peinado, María Amparo Antón, Santos, Rosa Latorre, Marín, María Asunción Palomar, García, María Carmen Botella, Fresquet, Eva Sánchez, Paños, Pedro Sala, Ruiz, Tomás Sánchez, Valero, Rosa Ana Valero, Vicente, María Seoane, Llinares, Magdalena Martín, Alegre, Antonio Masiá, Caro, José Luis Llisterri, Verdú, Irene Lluch, Carratala, Vicente Pallares, Roca, Francisco Valls, Pérez, Rafael Manuel Micó, García, Jacinto Espinosa, Romo, José Ignacio Prieto, Fernández, Leandro Fernández, Sierratapia, Javier, Regidor, Nieves Moreno, Sánchez, Francisco Javier Zaballos, Moreno, Ana Moreno, Barrera, Francisco Carramiñana, Vázquez, Juan José Torres, Samino, María José Gamero, Rodríguez, Miguel Ángel de Santiago, Martínez, Pablo Rafael Gómez, Becerra, Antonio Carlos Elías, Olivera, Javier Soto, Cambero, Víctor, Ávila, Julián Domínguez, Fuentes, Andrés Simón, Jiménez, Jorge Manuel de Nicolás, Fraile, Dimas Igual, Barco, Guadalupe Nieto, Ramos, Ignacio Araujo, Berrocal, María Luz Serrano, Ramírez, Francisco Buitrago, Marcos, Minerva Gallego, González, Félix Suárez, Carrasco, Victoriano Chavero, García, José Polo, Peguero, Francisco Guerra, Vega, Francisco Javier Sánchez, Mas, Manuel Tejero, Donoso, Alba Palmerín, Yedro, Miguel Turégano, Rojas, María Beatriz Esteban, Moreno, Fátima Cabezudo, Saldaña, Nawson Elver Quevedo, Fenés, María del Mar García, García, Alfonso Barquilla, Florencio, Timotea Garrote, Toro, José María Fernández, Rañal, Alejandra Rey, Río, Elena García del, Pol, Enrique Nieto, Fernández, Julio Álvarez, Álvarez, Pilar Alonso, Gómez, María Luisa Jorge, Guerrero, Antonio Calvo, Colomina, Isabel Celemín, Casal, Lucía Barreiro, Moreno, Juana Fernández, Martínez, María Angelines Carballal, Rodríguez, Nabor Díaz, Paredes, Carlos Moral, García, Dolores Recarey, Mato, Fco. Javier Iglesias, Ulloa, Antonio Fouz, González, Amparo Fidalgo, Parada, Noelia Dios, Sabarís, Patricia Conde, Pérez, Ana Isabel Rodríguez, Palacio, Ana Inés García, Varela, Víctor Julio Quesada, Iglesias, Lidia Romero, Llerena, Ángel Lado, Rodríguez, Carmen Lires, Diaz, María Luisa Carretero, Arias, José Carreira, Camino, Jose Luis Vázquez, Penas, María del Carmen Torreiro, Freire, Sandra Yáñez, Sanjurjo, Sergio Cinza, Aldana, Daniel Rey, Díaz, Carlos Piñeiro, Romanos, Fernando García, González, Antonia Moreno, Sastre, María Lara Amengual, Palli, Susana Martínez, Bauza, José Alfonso Ramón, Bolinches, José Ortiz, Fernández, Carmen Fernández, Vázquez, María Isabel Orlandis, Mezquita, Ana Sanchís, Aramburu, Fernando Unceta, Morant, Juan Fernando Peiró, Amengual, Ana Moyá, García, Isidro Godoy, Sevillano, Fernando Rubio, González, María Isabel González, Souto, Marta Pérez, Contreras, Raquel de León, González, Sara Isabel Almeida, Diez, Irene Almería, Sánchez, Virginia María Mirabal, Lavado, Francisco José Escobar, Pérez, Yoel Anta, Hernández, Nayra Sánchez, Jerez, Juan Luis Alonso, Koch, Ricardo, Mendoza, Nayra Ramírez, Hernández, Héctor Suárez, Escobar, Francisco Jesús Morales, Zancada, Sonsoles María Velilla, Sabarís, Rafael Crespo, Jiménez, Óscar Fernando Isaula, Puga, Jesús Manuel González, Ávila, Jorge Antonio Benaín, González, Óscar del Toro, Íñigo, Laura Sánchez, Pérez, Inés Sanz, Nubla, José Félix Zuazagoitia, Ituiño, Ana Echebarría, Tris, Gregorio Mediavilla, Bosch, María Carmen Noriega, González, Esther, Macho, María Luisa Ruiz, Olmo, Ruth Sendino del, Prado, Asunción Olagorta de, Muguerza, Ana López de Viñaspre, Iriso, Jesús Iturralde, Martínez, María José Pérez, Carbonell, Ana Piera, Fernández, Margarita Alonso, Cuadrado, María Montserrat Rueda, Rodríguez, Rodrigo Abad, Cabo, José Miguel Álvarez, Rodríguez, Rubén Sánchez, Cabo, Eva María Cano, Secin, Anny Romero, Díaz, Miguel Ángel Prieto, Fernández, Juan Jesús García, Bueno, Vicente Llorca, Pérez, Ana María Ballesteros, López, Domingo J. Rubira, Franco, María Dolores Esteve, Pablo, Elena Sánchez, López, María Teresa Palacios, Meroño, Juan Castillo, Martínez, José María Lobo, Martínez, Isabel María Peral, Carrasco, J. Eduardo Carrasco, and González, Armando Santo
- Abstract
Conocer la prevalencia de enfermedad renal crónica (ERC) y determinar los factores asociados al deterioro de la función renal en población asistida en atención primaria.
- Published
- 2021
- Full Text
- View/download PDF
43. Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma
- Author
-
Khanlari, Mahsa, Li, Shaoying, Miranda, Roberto N., Iyer, Swaminathan, Konoplev, Sergej, Lin, Pei, Yin, C. Cameron, Tang, Guilin, Qiu, Lianqun, Vega, Francisco, Medeiros, L. Jeffrey, and Xu, Jie
- Abstract
Several morphologic variants of ALK+ anaplastic large cell lymphoma (ALCL) are recognized. The small cell (SC) and lymphohistiocytic (LH) variants are reported to be associated with poorer outcome in children with ALK + ALCL. In this study of 102 adults with ALK + ALCL, there were 18 (18%) cases of SC and/or LH variants. Patients with SC/LH ALK + ALCL more often had peripheral blood involvement than patients with non-SC/LH neoplasms (60% vs 0%, p= 0.02). There were no other significant differences in clinical features between patients with SC/LH versus non-SC/LH ALK + ALCL. Compared with non-SC/LH cases of ALK + ALCL, neoplasms with SC/LH features were more often positive for CD2 (92% vs. 36%, p= 0.0007), CD3 (81% vs. 15%, p= 0.0001), CD7 (80% vs. 37%, p= 0.03), and CD8 (54% vs. 7%, p= 0.0006). There were no other significant differences in the immunophenotype between SC/LH and non-SC/LH ALK + ALCL cases. The initial chemotherapy regimens and the response rates were similar between patients with ALK + ALCL with SC/LH patterns versus those with non-SC/LH patterns. After a median follow-up of 30.8 months (range, 0.3–208 months), patients with high (>3) International Prognostic Index (IPI) scores had significantly shorter overall survival than patients with low (<3) IPI scores (p= 0.003). However, there was no significant difference in overall or progression-free survival between patients with SC/LH versus non-SC/LH ALK + ALCL (p= 0.99 and p= 0.94, respectively). We conclude that, in adults with ALK + ALCL, SC and LH variants are associated with peripheral blood involvement and a CD8 + immunophenotype with retention of T-cell markers (CD2, CD3, and CD7). However, in contrast with children with ALK + ALCL, SC and LH variants appear to have no impact on prognosis in adults with ALK + ALCL.
- Published
- 2021
- Full Text
- View/download PDF
44. Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling
- Author
-
Agarwal, Nitin K., Kim, Chae-Hwa, Kunkalla, Kranthi, Vaghefi, Amineh, Sanchez, Sandra, Manuel, Samantha, Bilbao, Daniel, Vega, Francisco, and Landgraf, Ralf
- Abstract
The oncoprotein Smoothened (SMO), a Frizzled-class-G-protein-coupled receptor, is the central transducer of hedgehog (Hh) signaling. While canonical SMO signaling is best understood in the context of cilia, evidence suggests that SMO has other functions in cancer biology that are unrelated to canonical Hh signaling. Herein, we provided evidence that elevated levels of human SMO show a strong correlation with elevated levels of insulin-like growth factor 1 receptor (IGF1R) and reduced survival in diffuse large B-cell lymphoma (DLBCL). As an integral component of raft microdomains, SMO plays a fundamental role in maintaining the levels of IGF1R in lymphoma and breast cancer cells as well IGF1R-associated activation of protein kinase B (AKT). Silencing of SMOincreases lysosomal degradation and favors a localization of IGF1R to late endosomal compartments instead of early endosomal compartments from which much of the receptor would normally recycle. In addition, loss of SMO interferes with the lipid raft localization and retention of the remaining IGF1R and AKT, thereby disrupting the primary signaling context for IGF1R/AKT. This activity of SMO is independent of its canonical signaling and represents a novel and clinically relevant contribution to signaling by the highly oncogenic IGF1R/AKT signaling axis.
- Published
- 2021
- Full Text
- View/download PDF
45. TOUT SUR LE CAFÉ.
- Author
-
PILON, CHARLINE-ÈVE, KADDOURI, HIND, and VEGA, FRANCISCO
- Published
- 2021
46. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
- Author
-
Caso, Raul, Sanchez-Vega, Francisco, Tan, Kay See, Mastrogiacomo, Brooke, Zhou, Jian, Jones, Gregory D., Nguyen, Bastien, Schultz, Nikolaus, Connolly, James G., Brandt, Whitney S., Bott, Matthew J., Rocco, Gaetano, Molena, Daniela, Isbell, James M., Liu, Yuan, Mayo, Marty W., Adusumilli, Prasad S., Travis, William D., and Jones, David R.
- Abstract
The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histologic subtypes in lung adenocarcinoma (LUAD).
- Published
- 2020
- Full Text
- View/download PDF
47. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers
- Author
-
El Hussein, Siba, Shaw, Kenna R. M., and Vega, Francisco
- Abstract
Recently, comprehensive genomic analyses have allowed a better molecular characterization of diffuse large B-cell lymphoma (DLBCL), offering novel opportunities in patient risk stratification and management. In the era of precision medicine, this has allowed us to move closer toward a more promising therapeutic outcome in the setting of DLBCL. In this review, we highlight the newly reported heterogeneous mutational landscapes of DLBCL (from two whole-exome sequencing studies, and from a more recent work targeting a 293-gene of a hematologic malignancy-designed panel. Altogether, these studies provide further evidence of the clinical applicability of genomic tests. We also briefly review established biomarkers in DLBCL (e.g., MYC and TP53), and our understanding of the germinal center cell reaction, including its epigenetic regulation, emphasizing some of the key epigenetic modifiers that play a role in lymphomagenesis, with available therapeutic targets. In addition, we present current data regarding the role of immune landscapes in DLBCL (inflamed versus non-inflamed), how the recently defined molecular DLBCL subtypes may affect the cellular composition of the tumor microenvironment and the function of the immune cells, and how this new knowledge may result in promising therapeutic approaches in the near future.
- Published
- 2020
- Full Text
- View/download PDF
48. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma
- Author
-
Yang, Chen, Sanchez-Vega, Francisco, Chang, Jason C., Chatila, Walid K., Shoushtari, Alexander N., Ladanyi, Marc, Travis, William D., Busam, Klaus J., and Rekhtman, Natasha
- Abstract
Primary pulmonary melanoma (PPM) is an entity recognized by the thoracic WHO classification. However, given the absence of native melanocytes in the lung and the known phenomenon of regression of cutaneous melanomas, the existence of PPM has remained controversial. Herein we investigate clinicopathologic and genomic features of lung-only melanomas with the goal to clarify their site of origin. We identified 10 melanomas involving exclusively lung with no current or previous cutaneous, uveal, or mucosal primaries. Four patients had solitary lesions with mean size of 5.1 cm (range 3.0–10.1 cm), meeting the criteria of PPM. Four patients had 2–3 lesions and 2 patients had >10 lesions. All cases underwent targeted next-generation sequencing interrogating up to 468 cancer genes, which revealed mean tumor mutation burden of 42.6 per megabase (range 1.8 to 126) and frequent mutations involving BRAF, NRAS, NF1, KIT, and KRAS– a genomic profile typical of UV-associated cutaneous melanoma. Mutational signature was assessable for eight cases harboring >20 mutations. This revealed that all evaluable cases harbored a dominant UV signature. In addition, one nonevaluable case harbored a GG > AA TERTpromoter variant that is highly specific for UV-mutagenesis. As control groups, using the same methodology, a dominant UV signature was identified in 97% (470/486) of cutaneous melanomas, whereas no lung adenocarcinoma (n= 291) exhibited this signature. Notably, the clinical and pathologic features of solitary melanomas, especially those with large size and epithelioid morphology, closely mimicked primary lung carcinomas, highlighting a major potential for misdiagnosis. In conclusion, presence of a UV signature provides direct evidence that nearly all lung-only melanomas in this series, including solitary lesions meeting the strict criteria of PPM, represent metastases from occult cutaneous melanomas. This suggests that lung-only melanomas should be considered as likely metastatic even in the absence of a known primary melanoma elsewhere.
- Published
- 2020
- Full Text
- View/download PDF
49. A new fossil frog crab (Brachyura, Raninoidea) from the Paleogene of northeastern Pacific
- Author
-
Nyborg, Torrey, Pasini, Giovanni, Garassino, Alessandro, van Bakel, Barry W.M., Vega, Francisco J., and Nyborg, Brant
- Abstract
One new genus and two new species of fossil frog crabs from the Eocene to Oligocene deposits of Washington State (USA) and Vancouver Island (British Columbia, Canada) of the northeastern Pacific are described, based upon several well-preserved specimens. The studied specimens are herein described as Amphoranina blandi n.?gen., n.?sp. and A. multispinata n. gen, n.?sp. (Raninidae De Haan, 1839) respectively. Amphoranina n.?gen. appears to be endemic to the middle to upper Paleogene of the northeastern Pacific.
- Published
- 2020
- Full Text
- View/download PDF
50. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups
- Author
-
Yang, Soo-Ryum, Bouhlal, Yosr, De La Vega, Francisco M., Ballard, Morgan, Kuo, Calvin J., Vilborg, Anna, Jensen, Greg, and Allison, Kimberly
- Abstract
In patients with invasive breast cancer, fluorescence in situ hybridization (FISH) testing for HER2 typically demonstrates the clear presence or lack of ERBB2(HER2) amplification (i.e., groups 1 or 5). However, a small subset of patients can present with unusual HER2FISH patterns (groups 2–4), resulting in diagnostic confusion. To provide clarity, the 2018 CAP/ASCO HER2 testing guideline recommends additional testing using HER2 immunohistochemistry (IHC) for determining the final HER2 status. Despite this effort, the genomic correlates of unusual HER2FISH groups remain poorly understood. Here, we used droplet digital PCR (ddPCR) and targeted next-generation sequencing (NGS) to characterize the genomic features of both usual and unusual HER2FISH groups. In this study, 51 clinical samples were selected to represent FISH groups 1–5. Furthermore, group 1 was subdivided into two groups, with groups 1A and 1B corresponding to cases with HER2signals/cell ≥6.0 and 4–6, respectively. Overall, our findings revealed a wide range of copy number alterations in HER2across the different FISH groups. As expected, groups 1A and 5 showed the clear presence and lack of HER2copy number gain, respectively, as measured by ddPCR and NGS. In contrast, group 1B and other uncommon FISH groups (groups 2–4) were characterized by a broader range of HER2copy levels with only a few select cases showing high-level gain. Notably, these cases with increased HER2copy levels also showed HER2 overexpression by IHC, thus highlighting the correlation between HER2copy number and HER2 protein expression. Given the concordance between the genomic and protein results, our findings suggest that HER2 IHC may inform HER2copy number status in patients with unusual FISH patterns. Hence, our results support the current recommendation for using IHC to resolve HER2 status in FISH groups 2–4.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.